Provided by Tiger Fintech (Singapore) Pte. Ltd.

Outlook Therapeutics, Inc.

1.96
-0.0900-4.39%
Volume:893.61K
Turnover:1.79M
Market Cap:83.99M
PE:2.37
High:2.05
Open:2.05
Low:1.95
Close:2.05
Loading ...

Outlook Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CEO Robert Jahr

Reuters
·
10 Jul

Outlook Therapeutics appoints Bob Jahr as CEO

TIPRANKS
·
01 Jul

Outlook Therapeutics Inc - Lawrence a. Kenyon to Continue as CFO and Board Member

THOMSON REUTERS
·
01 Jul

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

THOMSON REUTERS
·
01 Jul

Press Release: Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Dow Jones
·
01 Jul

BRIEF-Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD

Reuters
·
10 Jun

Outlook Therapeutics® Announces SMC Recommendation of Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet Amd

THOMSON REUTERS
·
10 Jun

BRIEF-Outlook Therapeutics Announces Commercial Launch Of Lytenava In Germany And UK For Treatment Of Wet AMD

Reuters
·
02 Jun

Outlook Therapeutics® Announces Commercial Launch of Lytenava™ (Bevacizumab Gamma) in Germany and the UK for the Treatment of Wet Amd

THOMSON REUTERS
·
02 Jun

Outlook Therapeutics Inc - Lytenava Approved for Wet Amd in EU and UK

THOMSON REUTERS
·
02 Jun

BRIEF-Outlook Therapeutics Announces Pricing Of $13.0 Million Public Offering

Reuters
·
23 May

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

THOMSON REUTERS
·
23 May

Outlook Therapeutics Plans Share Offering; Stock Declines After Hours

MT Newswires Live
·
23 May

Outlook Therapeutics announces common stock, warrants offering

TIPRANKS
·
23 May

Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Outlook Therapeutics Inc - FDA Pdufa Goal Date for Lytenava Set for August 27, 2025

THOMSON REUTERS
·
16 May

Outlook Therapeutics Inc - Lytenava Planned for Launch in Germany and UK in Q2 Cy2025

THOMSON REUTERS
·
16 May

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

THOMSON REUTERS
·
16 May

Outlook Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview

Reuters
·
12 May

BRIEF-Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA Resubmission - SEC Filing

Reuters
·
09 Apr